Exco InTouch, a provider of mobile patient engagement and communication solutions for the pharmaceutical and healthcare sectors, has announced the appointment of Madhav Vattikuti as its Chief Technology Officer (CTO).
Vattikuti’s role will see him use his significant technology expertise and background to strengthen delivery and development of Exco InTouch’s market-leading mobile technology into vertical markets such as eClinical, mHealth and Late Phase.
He joins the company from Merge Clinical, where he worked as vice president of research and development. He brings a proven track record of developing products in the clinical sector and has more than 17 years’ experience in software development.
Holding a degree in computer science from the University of Poona, he started his career in India before moving to the US, where he worked at multiple companies including Etrials Worldwide.
His appointment to Exco comes on the back of a successful year of growth for the company. In 2011, the firm received a growth investment from leading equity and venture capital group, Scottish Equity Partners (SEP), in addition to winning several prestigious awards. These included the European Outsourcing Award for Best eBusiness/IT strategy , and the Deloitte Fast 50 Technology Award , which recognises the fastest-growing technology companies in the UK.
“I am delighted to join Exco InTouch as the new CTO and to lead what I view as a game-changing opportunity to change the patient engagement landscape through the use of mobile technology”, said Vattikuti.
“I look forward to optimising the delivery of Exco InTouch’s existing solutions, in addition to leading the expansion of new product lines in line with the company’s proven strategy of innovation and partnership.”
Tim Davis, the company’s chief executive, added: “Despite economic uncertainty, the past five years have proved highly successful for Exco InTouch, with recent significant appointments representing the next phase of growth for the company. As we start 2012, our unique team of experts and innovators makes us better positioned than ever to provide mobile technology solutions that ensure optimised patient engagement in the healthcare and drug development sectors.”
